TARGETed Therapy Drug MONITOring in DIGestive Oncology

Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic colorectal cancer (mCRC), hepatocellular carcinoma (HCC), gastroenteropancreatic neuroendocrine tumor (gepNET), or pancreatic neuroendocrine tumor (pNET)), with the aim of determine the optimal dose adapted for each patient, in the future.

Trial Details

NCT ID
NCT05443087
Phase
NA
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Blood sampling to build population pharmacokinetics model
Locations (sample)
  • Amiens, France|49.9,2.3
  • Auxerre, France|47.7996,3.57033
  • Avignon, France|43.94834,4.80892
  • Bayeux, France|49.27732,-0.7039
  • Clermont-Ferrand, France|45.77969,3.08682

Key Eligibility Criteria

  • Patient aged 18 years or over
  • Advanced digestive cancer (histologically confirmed or confirmed by imaging for HCC) for which a standard treatment (according to each drug SmPC an…
  • Regorafenib for GIST, mCRC, and HCC,
  • Everolimus for gepNET,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →